J. T. Chang

This study identifies intestinal regulatory T cells producing IL-27 to specifically regulate Th17 immunity in the gut, revealing a novel mechanism for tissue-specific immune control.

The paper shows cancer cells in resistant tumors promote immune-suppressive macrophages, reducing T-cell activation, and suggests balancing cell cycle inhibition with immune activation for better therapy.

This study shows that lncRNA Malat1 restricts Th17 cell IL-17A production by regulating a bivalent super-enhancer, thereby controlling intestinal inflammation resolution.

This study shows that RORγt serine 182 regulates T cell heterogeneity in the intestine, maintaining homeostasis and limiting inflammation.

This study examines how breast cancer tumors evolve during early stage treatment with combination CDK and endocrine inhibitors, finding convergent resistance pathways and increased subclonal diversity with combination therapy.

This study identifies a terminally differentiated effector memory CD8 T cell population with unique molecular and functional properties that challenge classical definitions of effector memory cells.

The paper shows that immune cell dynamics in peripheral blood reflect tumor-immune interactions during immunotherapy, with responder patients showing increased cytotoxic differentiation and interferon signaling.

This study identifies a sequential therapy strategy using HDAC inhibitors to reverse chemotherapy-induced resistance in ER+ breast cancer by targeting cancer stem cell-like traits.

This study identifies distinct CD8+ T cell subsets in non-lymphoid tissues during infection and cancer, revealing their functional roles and regulatory mechanisms.

The paper identifies novel conjugated bile acids produced by the microbiome in mice and humans using mass spectrometry and a murine 3D model.